Mirum Pharmaceuticals, Inc. MIRM Bile Acid Medicines — Product sales, net
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Mirum Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Mirum Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mirum Pharmaceuticals, Inc.'s bile acid medicines — product sales, net.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mirum Pharmaceuticals, Inc.'s bile acid medicines — product sales, net?
- Mirum Pharmaceuticals, Inc. (MIRM) reported bile acid medicines — product sales, net of $46.08M in Q1 2026.
- How has Mirum Pharmaceuticals, Inc.'s bile acid medicines — product sales, net changed year-over-year?
- Mirum Pharmaceuticals, Inc.'s bile acid medicines — product sales, net increased by 20.1% year-over-year, from $38.36M to $46.08M.
- What does bile acid medicines — product sales, net mean?
- This metric represents the total net revenue generated from the commercial sale of bile acid inhibitor therapies, specifically targeting rare cholestatic liver diseases. It reflects the company's ability to successfully market and distribute specialized orphan drug products to healthcare providers and patients. This figure is calculated after accounting for deductions such as rebates, returns, and discounts associated with the product line.